A flexible & fully automated process for CAR T cell manufacturing

Cell & Gene Therapy Insights 2022; 8(10), 1267;

DOI: 10.18609/cgti.2022.185

Published: 11 November 2022
FastFacts
Sophia Lollies


Watch the video or read the poster to learn more about:

  • Current challenges in manufacturing CAR-T cells and approaches to overcoming these 
  • An overview of Miltenyi Biotec´s cell manufacturing platform and a deep dive into CliniMACS Prodigy® Instrument components
  • Insights into the fully automated CAR -T cell manufacturing process
  • Options for non-viral engineering

Sophia Lollies is a Global Product Manager for the clinical engineered cells portfolio at Miltenyi Biotec. Since 2021 she has been working with the R&D and Clinical Development teams to advance the development of CAR and TCR T cell therapy enabling tools, with a particular focus on CAR T cell immunotherapy. Prior to this, Sophia supported the development of clinical applications on the CliniMACS® Prodigy for industrial customers. Additionally, she gained relevant experience from Bayer AG in the field of Global Screening and Automation, following the completion of her MSc in Life and Medical Sciences at the LIMES Institute in Bonn, Germany.



View pdf






We hope you enjoyed this FastFacts video. You can also view the poster summary here.






Authorship & conflict of interest

Contributions: All named authors take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Acknowledgements: None

Disclosure and potential conflicts of interest: The author declares that they have no conflicts of interest.

Funding declaration: The author received no financial support for the research, authorship and/or publication of this article. 


Article & copyright information

Copyright: Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Attribution: Copyright © 2022 Miltenyi Biotec B.V. & CO. KG. Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0.

Article source: From a Fast Facts video recorded on: Sep 16 2022; Publication date: Nov 10 2022.


This article is part of the Cell therapy bioprocessing spotlight